Trial · NCT00041080

Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00041080, Phase 3, Completed, National Cancer Institute (NCI); results first posted 2013-09-16

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Trials, record NCT00041080. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00041080

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT number: NCT00041080
Status: Completed
Phases: Phase 3
Enrollment: 139 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: tamoxifen citrate, thalidomide, laboratory biomarker analysis
First posted: 2003-01-27
Last updated: 2019-07-30
Results first posted: 2013-09-16

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Median Progression-free Survival	from enrollment onto the study until first disease progression or death due to any cause

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Median Progression-free Survival	from enrollment onto the study until first disease progression or death due to any cause		months	MEDIAN

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Median Progression-free Survival	Grp - 1		3.2	95% Confidence Interval 2.7 to 3.9	months
Median Progression-free Survival	Grp - 2		4.5	95% Confidence Interval 2.7 to 5.5	months

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Grp - 1	69
Overall Study	STARTED	Grp - 2	70
Overall Study	COMPLETED	Grp - 1	39
Overall Study	COMPLETED	Grp - 2	60
Overall Study	NOT COMPLETED	Grp - 1	30
Overall Study	NOT COMPLETED	Grp - 2	10

Source ClinicalTrials.gov

Adverse events66

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Leukopenia	Blood and lymphatic system disorders	Grp - 1	25	67
other	Leukopenia	Blood and lymphatic system disorders	Grp - 2	8	69
other	Neutropenia	Blood and lymphatic system disorders	Grp - 1	21	67
other	Neutropenia	Blood and lymphatic system disorders	Grp - 2	5	69
other	Thrombocytopenia	Blood and lymphatic system disorders	Grp - 1	6	67
other	Thrombocytopenia	Blood and lymphatic system disorders	Grp - 2	4	69
other	Anemia	Blood and lymphatic system disorders	Grp - 1	15	67
other	Anemia	Blood and lymphatic system disorders	Grp - 2	10	69
other	DVT/thrombosis	Cardiac disorders	Grp - 1	4	67
other	DVT/thrombosis	Cardiac disorders	Grp - 2	1	69

1 to 10 of 66Source ClinicalTrials.gov

See all 66 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Grp - 1
Total, all-cause mortality	Grp - 2
Total, other adverse events	Grp - 1	42	67
Total, other adverse events	Grp - 2	24	69
Total, serious adverse events	Grp - 1	3	67
Total, serious adverse events	Grp - 2	1	69

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA027469	Gynecologic Oncology Group	DISAIA, PHILIP J.	GYNECOLOGIC ONCOLOGY GROUP	NATIONAL CANCER INSTITUTE	1985 to 2013

Source NIH RePORTER

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Grp - 1 vs Grp - 2: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00041080

GET https://conductscience.org/api/trials/v1/NCT00041080/events?page=2

API reference For AI assistants